Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9623873 | 0.93 | CYP1A2 (0.46) | CYP1A2HTTLMNAMAPK1MAPT | |
| SCHEMBL1352156 | 0.87 | CYP1A2 (0.45) | CYP1A2HTTLMNAMAPK1POLB | |
| SCHEMBL178299 | 0.86 | ALDH1A1 (0.36) | CYP1A2HTTLMNAMAPTGAA | |
| SCHEMBL11701365 | 0.81 | ALDH1A1 (0.43) | CYP1A2HTTLMNAMAPK1POLB | |
| SCHEMBL1353080 | 0.79 | GAA (0.44) | CYP1A2HTTLMNAMAPK1POLB | |
| SCHEMBL11704781 | 0.79 | GAA (0.44) | CYP1A2HTTLMNAMAPK1POLB | |
| SCHEMBL9623123 | 0.79 | GAA (0.44) | CYP1A2HTTLMNAMAPK1POLB | |
| SCHEMBL5482504 | 0.79 | KDM4E (0.35) | CYP1A2ALDH1A1KDM4E | |
| SCHEMBL16641770 | 0.78 | PIN1 (0.33) | CYP1A2ALDH1A1KDM4E | |
| SCHEMBL5691762 | 0.77 | CYP1A2 (0.74) | CYP1A2HTTLMNAMAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3478662-B1 | AZADECALIN DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO5) LTD (GB) | 2020-09-16 | — | — | EP | disclosed |
| US-20170015631-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY, INC. | 2017-01-19 | — | — | US | disclosed |
| US-6727294-B2 | RADIATION TRANSPARENT MOLDING MATERIALS | MITSUBISHI ENGINEERING-PLASTICS CORPORATION (JP) | 2004-04-27 | — | — | US | disclosed |
| EP-0794218-B1 | Polycarbonate resin composition stabilized against radiation | MITSUBISHI ENG PLASTICS CORP (JP) | 2003-10-15 | — | — | EP | disclosed |
| EP-0753540-B1 | Polycarbonate resin composition | MITSUBISHI ENG PLASTICS CORP (JP) | 2003-06-11 | — | — | EP | disclosed |
| US-6359028-B1 | USED IN MEDICAL EQUIPMENT, DISCOLORATION INHIBITION | MITSUBISHI ENGINEERING-PLASTICS CORPORATION (JP) | 2002-03-19 | — | — | US | disclosed |
| US-20010034419-A1 | Radiation transparent molding materials | MITSUBISHI ENGINEERING-PLASTICS CORPORATION (JP) | 2001-10-25 | — | — | US | disclosed |
| US-6040367-A | EXCELLENT RESISTANCE TO AN IONIZING RADIATION, IN WHICH HETEROCYCLIC COMPOUND CONTAINING OXYMETHYLENE UNITS | MITSUBISHI ENGINEERING-PLASTICS CORPORATION (JP) | 2000-03-21 | — | — | US | disclosed |
| US-5977206-A | Polycarbonate resin composition | MITSUBISHI ENGINEERING-PLASTICS CORP. (JP) | 1999-11-02 | — | — | US | disclosed |
| US-5948838-A | 0.01 TO 5 PARTS BY WEIGHT OF A COMPOUND CONTAINING OXYMETHYLENE UNIT | MITSUBISHI ENGINEERING-PLASTICS CORP. (JP) | 1999-09-07 | — | — | US | disclosed |
| EP-0794218-A2 | Polycarbonate resin composition stabilized against radiation | MITSUBISHI ENGINEERING-PLASTICS CORPORATION (JP) | 1997-09-10 | — | — | EP | disclosed |
| EP-0753540-A2 | Polycarbonate resin composition | MITSUBISHI ENGINEERING-PLASTICS CORPORATION (JP) | 1997-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170015631-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | PDK1, PDK2, PKM | CYP1A2 2145/4885HTT 2553/4885LMNA 1822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.